Clinical Drug Investigation

, Volume 29, Issue 2, pp 79–86 | Cite as

Safety and Tolerability of Fluticasone Furoate Nasal Spray Once Daily in Paediatric Patients Aged 6–11 Years with Allergic Rhinitis

Subanalysis of Three Randomized, Double-Blind, Placebo-Controlled, Multicentre Studies
  • Eli O. Meltzer
  • Ita Tripathy
  • Jorge F. Máspero
  • Wei Wu
  • Ed Philpot
Original Research Article


Background: Fluticasone furoate is a novel enhanced-affinity corticosteroid that has demonstrated favourable safety and tolerability in paediatric patients. Three pivotal phase III studies were conducted in children as young as 2 years of age; however, because the European Medicines Agency has recently approved fluticasone furoate for use in children aged ≥6 years, a subanalysis has been conducted to support safety and tolerability in the 6- to 11-year age group.

Methods: All three trials included in the subanalysis were randomized, double-blind, placebo-controlled, parallel-group studies: a 2-week US study in patients with seasonal allergic rhinitis (SAR), a 12-week global study in patients with perennial allergic rhinitis (PAR) and a 6-week US hypothalamic-pituitary-adrenal (HPA) axis safety study in patients with PAR. Randomized patients received once-daily treatment with either fluticasone furoate nasal spray (FFNS) 55 εg (n = 297; 2-week SAR and 12-week PAR studies only), FFNS 110 εg (n = 321) or vehicle placebo nasal spray (n = 330). Safety assessments included clinical adverse event (AE) monitoring, clinical laboratory tests, detailed nasal examinations, monitoring of vital signs, and 12-lead ECGs. Ophthalmic examinations (12-week PAR study only) were conducted by an ophthalmologist or optometrist before randomization and at final treatment visit. Twenty-four-hour urinary cortisol (UC) excretions (6- and 12-week PAR studies) and serum Cortisol (SC) concentrations (6-week PAR study only) were assessed at specified timepoints over 24 hours as a measure of HPA axis function. In the 6-week HPA axis safety study in patients with PAR, 24-hour UC and SC samples were collected in a domiciled (clinical) setting.

Results: No unexpected safety results were observed in patients aged 6–11 years enrolled in the three studies. Across all three trials, AEs considered by the investigator to be drug related were observed in 10%, 7% and 8% of patients in the FFNS 55 εg, FFNS 110 εg and placebo groups, respectively. The most common AEs were headache (8%, 9% and 8% in the FFNS 55 εg, FFNS 110 εg and placebo groups, respectively), nasopharyngitis (5%, 6% and 5%, respectively), pharyngolaryngeal pain (5%, 3% and 4%, respectively), epistaxis (4% in both active treatment groups and 4% in the placebo group) and pyrexia (3% in both active treatment groups and 2% in the placebo group). Findings from nasal examinations were similar across the treatment and placebo groups. Ophthalmic examinations found no differences between the treatment groups for mean change from baseline in intraocular pressure (assessed in the 12-week PAR study only), and no posterior subcapsular cataracts were reported in patients in either FFNS-treatment group. In the 6-week HPA axis study, 24-hour SC geometric mean concentrations were similar for FFNS and placebo groups. The lower limit of two-sided 95% confidence interval (CI) for the treatment ratio was greater than the prespecified noninferiority margin of 0.8 (treatment ratio = 0.92, 95% CI 0.80, 1.05).

Conclusions: FFNS has a favourable safety and tolerability profile in patients aged 6–11 years with PAR or SAR.


  1. 1.
    Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000; 105(6 Pt 2): S616–21PubMedCrossRefGoogle Scholar
  2. 2.
    Berger WE. Allergic rhinitis in children: diagnosis and management strategies. Paediatr Drugs 2004; 6(4): 233–50PubMedCrossRefGoogle Scholar
  3. 3.
    Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007; 120(2): 381–7PubMedCrossRefGoogle Scholar
  4. 4.
    Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63Suppl. 86: 8–160PubMedCrossRefGoogle Scholar
  5. 5.
    Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81(5 Pt 2): 478–518PubMedCrossRefGoogle Scholar
  6. 6.
    Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001; 108(1 Suppl. 2): S45–53PubMedCrossRefGoogle Scholar
  7. 7.
    Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001; 22(4): 185–9PubMedGoogle Scholar
  8. 8.
    Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82(3): 233–48PubMedCrossRefGoogle Scholar
  9. 9.
    Thompson AK, Juniper E, Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 2000; 85(5): 338–47PubMedCrossRefGoogle Scholar
  10. 10.
    Bellanti JA, Wallerstedt DB. Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc 2000; 21(6): 367–70PubMedCrossRefGoogle Scholar
  11. 11.
    Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104(1): 107–14PubMedCrossRefGoogle Scholar
  12. 12.
    Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51(5): 400–9PubMedCrossRefGoogle Scholar
  13. 13.
    Stanbury RM, Graham EM. Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998; 82(6): 704–8PubMedCrossRefGoogle Scholar
  14. 14.
    Bousquet J, van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003; 58(3): 192–7PubMedCrossRefGoogle Scholar
  15. 15.
    Tattersfield AE, Harrison TW, Hubbard RB, et al. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1(3): 171–5PubMedCrossRefGoogle Scholar
  16. 16.
    International Rhinitis Management Working Group. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy 1994; 49(19 Suppl.): 1–34Google Scholar
  17. 17.
    van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55(2): 116–34PubMedCrossRefGoogle Scholar
  18. 18.
    Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007; 8: 54PubMedCrossRefGoogle Scholar
  19. 19.
    Máspero JF, Rosenblut A, Finn A, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg 2008; 138(1): 30–7PubMedCrossRefGoogle Scholar
  20. 20.
    Meltzer EO, Lee J, Tripathy I, et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 weeks. Pediatr Allergy Immunol. Epub 2008 Aug 1Google Scholar
  21. 21.
    Tripathy I, Levy A, Ratner P, et al. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol. Epub 2008 Oct 30Google Scholar
  22. 22.
    Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007; 29(7): 1415–20PubMedCrossRefGoogle Scholar
  23. 23.
    Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998; 101(2 Pt 1): 157–62PubMedCrossRefGoogle Scholar
  24. 24.
    Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19(6): 1330–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Eli O. Meltzer
    • 1
  • Ita Tripathy
    • 2
  • Jorge F. Máspero
    • 3
  • Wei Wu
    • 4
  • Ed Philpot
    • 4
  1. 1.Allergy and Asthma Medical Group and Research CenterSan DiegoUSA
  2. 2.Phelps County Regional Medical CenterRollaUSA
  3. 3.Allergy and Respiratory Research UnitFundacion CIDEABuenos AiresArgentina
  4. 4.Research and DevelopmentGlaxoSmithKlineResearch Triangle ParkUSA

Personalised recommendations